More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.60B
EPS
8.19
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.395645
Previous close
$43.68
Today's open
$43
Day's range
$41.43 - $43.95
52 week range
$19.76 - $48.78
show more
CEO
Kevin Koch
Employees
127
Headquarters
Boulder, CO
Exchange
Nasdaq Global Select
Shares outstanding
109482763
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management will participate in the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Fireside chat: Tuesday, November 10, 2026 at 8:00 am ET 2026 Truist Biopharma Symposium Fireside chat: Thursday, November 12, 2026 at 10:30 am ET The webcasts can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference.
PRNewsWire • Nov 9, 2026

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO ₂ as the primary endpoint – – STRATUS-HCM on track to start in the fourth quarter of 2026 – BOULDER, Colo., Nov. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced favorable feedback from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for EDG-7500 in symptomatic obstructive and nonobstructive hypertrophic cardiomyopathy (HCM).
PRNewsWire • Nov 5, 2026

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 – – Dosed first patient in Phase 2 EQUINOX-HFpEF trial of EDG-15400 in heart failure with preserved ejection fraction (HFpEF) – BOULDER, Colo., Nov. 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights.
PRNewsWire • Nov 4, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that on October 30, 2026, Edgewise granted inducement stock options to purchase a total of 17,250 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 8,626 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
PRNewsWire • Nov 2, 2026

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 – BOULDER, Colo., Oct. 8, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a Phase 2 clinical trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF) who have a left ventricular ejection fraction (LVEF) of at least 50%.
PRNewsWire • Oct 8, 2026

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
Seeking Alpha • Sep 22, 2026

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host webcast to discuss these findings today at 8:30 a.m. Eastern Time - BOULDER, Colo.
PRNewsWire • Sep 22, 2026

Biotech Options Buzz: UTHR, NMRA, EWTX
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
Schaeffers Research • Sep 18, 2026

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany.
PRNewsWire • Aug 24, 2026

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Edgewise Therapeutics (EWTX) has transformed into a well-capitalized cardiovascular drug developer following the $1.55B sale of sevasemten to Servier. EDG-7500, EWTX's lead asset, demonstrated robust Phase 2 efficacy in both obstructive and nonobstructive HCM, with a differentiated safety and workflow profile. EWTX's cash runway now extends into the early 2030s, enabling late-stage pipeline advancement without shareholder dilution and retaining up to $1.1B in milestone upside.
Seeking Alpha • Aug 18, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Edgewise Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.